Cogstate (ASX:CGS): Record Sales Pipeline, Favourable Margins and Global Expansion in Focus

Aditi Sarkar

20 August 2026 08:23 PM AEST

Cogstate (ASX:CGS): Record Sales Pipeline, Favourable Margins and Global Expansion in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cogstate (ASX:CGS) closed at AUD 3.08, up 5.12% on 20 August 2026.
The company provides neuroscience measurement technologies for central nervous system (CNS) clinical trials.
FY26 results highlighted record sales contracts of US$89.0 million, up 116% compared with FY25.
Investors continue to monitor clinical trial demand, AI-enabled technology investment, margins and contracted Revenue growth.

Cogstate Limited (ASX:CGS) shares closed at AUD 3.08, up 5.12% on 20 August 2026. The movement reflects a stronger Trading session as investors continue to assess the company’s neuroscience technology platform, clinical trial Demand and expanding contracted revenue base.

Daily share price movements can reflect changes in investor sentiment, trading activity, valuation expectations and broader market conditions. However, a single-session movement does not necessarily indicate a change in the company’s underlying fundamentals, financial position or long-term operating outlook.

Cogstate operates as a neuroscience endpoint technology company specialising in measurement solutions for central nervous system (CNS) clinical trials. The company provides digital cognitive assessments, analytics and technology-enabled solutions used by pharmaceutical and biotechnology companies developing therapies for neurological and psychiatric conditions.

The broader Australian market closed higher on the day. The S&P/ASX 200 (ASX:XJO) closed at 9,083.80 points, up 0.33% today, while the S&P/ASX 300 (ASX:XKO) closed at 9,019.90 points, up 0.37% today. Within the healthcare sector, the S&P/ASX 200 Health Care (ASX:XHJ) closed at 32,044.30 points, up 1.39% today.

Neuroscience data and clinical trial platform

Cogstate operates within the healthcare technology sector, providing specialised digital measurement tools that support clinical research and healthcare applications.

The company’s core Business focuses on improving the accuracy and efficiency of CNS Clinical Trials through digital cognitive testing, data quality programs, analytics and technology-enabled trial solutions.

Investors generally assess healthcare technology companies through factors such as contracted revenue growth, customer relationships, clinical trial activity, technology adoption, margins and scalability.

Cogstate’s business model is closely linked to pharmaceutical and biotechnology research activity, particularly in areas such as Alzheimer’s disease, psychiatric disorders, sleep disorders, rare diseases and other neurological conditions.

The company’s technology platform allows it to participate in multiple therapeutic areas rather than relying on a single Drug Development program. This provides exposure to broader CNS research activity while requiring continued Investment in technology, workflow systems and automation.

FY26 performance and growth update

Cogstate’s FY26 results highlighted record financial and commercial performance for the year ended 30 June 2026. The company reported record sales contracts of US$89.0 million, up 116% compared with FY25 sales contracts of US$41.3 million. Group revenue increased 15% to US$60.9 million from US$53.1 million in FY25.

The company reported EBITDA of US$18.3 million with a 30% margin, while EBIT reached US$15.2 million with a 25% margin. Profit before tax was US$16.1 million and profit after tax was US$11.9 million, representing Earnings Per Share of US$0.0696.

Cogstate generated cash inflow of US$8.5 million during FY26, with year-end cash balance of US$34.8 million. The company also declared a fully franked annual Dividend of AUD 0.04 per ordinary share.

Clinical Trials revenue remained the primary contributor, with FY26 clinical trial revenue of US$58.4 million compared with US$50.6 million in FY25. Healthcare revenue was US$2.5 million compared with US$2.5 million in the prior year.

Cogstate entered FY27 with contracted future revenue of US$118.5 million, up 32% from US$90.0 million at 30 June 2025. Of this amount, US$48.3 million is expected to be recognised as revenue in FY27, representing a 54% increase compared with the prior year.

The company also highlighted continued investment in systems, workflow orchestration, automation and AI-supported delivery to support scalable growth across its CNS clinical trial platform.

Investors continue to monitor whether Cogstate can convert its growing contracted revenue pipeline into sustained earnings growth while expanding its technology capabilities.

Factors investors generally monitor

Cogstate’s performance is influenced by pharmaceutical research activity, clinical trial demand, technology adoption and contract execution.

Contract wins are a key focus area because clinical trial businesses often recognise revenue over the duration of contracts. Investors generally monitor sales contracts, contracted future revenue and the timing of revenue recognition.

Demand for CNS clinical trials remains important. Growth in research activity across Alzheimer’s disease, psychiatric conditions and other neurological areas can influence opportunities for companies providing trial measurement solutions.

Technology investment is another consideration. Cogstate continues investing in automation, workflow systems and AI-enabled delivery capabilities to improve scalability and operational efficiency.

Margins are closely monitored because clinical trial technology businesses balance scientific expertise, service delivery costs and investment in future capabilities.

Customer Diversification is also relevant. Investors assess whether revenue growth is supported by a broad range of pharmaceutical and biotechnology partners rather than reliance on a limited number of customers.

Understanding the share price movement

Cogstate’s 5.12% share price increase on 20 August 2026 may reflect changes in investor sentiment, trading activity or positioning within the healthcare sector. However, daily share price movements alone do not necessarily represent changes in the company’s underlying fundamentals.

Healthcare technology companies can experience short-term Volatility as investors reassess contract growth, earnings visibility and future expansion opportunities.

For Cogstate, investors are likely to continue monitoring clinical trial demand, contracted revenue conversion, technology investment and the company’s ability to maintain growth across CNS research markets.

Conclusion

Cogstate (ASX:CGS) closed at AUD 3.08, up 5.12% on 20 August 2026. The company continues to provide neuroscience measurement technology supporting global CNS clinical trials.

While the daily share price movement reflects market activity, investors generally assess Cogstate through broader factors including contracted sales growth, revenue visibility, margins, technology investment and clinical research demand. FY26 results highlighted record sales contracts, increased revenue, strong profitability and a larger contracted revenue base entering FY27.

FAQs

Q: What was Cogstate’s share price movement on 20 August 2026?

A: Cogstate (ASX:CGS) closed at AUD 3.08, up 5.12% on 20 August 2026.

Q: What does Cogstate do?

A: Cogstate provides neuroscience measurement technologies and digital cognitive testing solutions for CNS clinical trials.

Q: What were Cogstate’s key FY26 results?

A: Cogstate reported revenue of US$60.9 million, EBITDA of US$18.3 million, profit after tax of US$11.9 million and record sales contracts of US$89.0 million in FY26.

Q: What is Cogstate’s contracted future revenue position?

A: Cogstate reported contracted future revenue of US$118.5 million at 30 June 2026, including US$48.3 million expected to be recognised in FY27.

Q: What factors influence Cogstate’s outlook?

A: Investors generally monitor clinical trial demand, contract wins, revenue conversion, technology investment, margins and customer relationships.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.